| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/28/2005 | CN1220684C 2, 4, Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/28/2005 | CN1220683C Acyl derivatives for treating VLA-4 related disorders |
| 09/28/2005 | CN1220493C New application of lactose derivative |
| 09/28/2005 | CN1220488C Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction |
| 09/28/2005 | CN1220451C 健康食品 Healthy Food |
| 09/27/2005 | US6949655 Acyclic piperidine derivatives |
| 09/27/2005 | US6949653 A chemical intermediate reaction by starting 2,6-diaminopyridine with malic acid and sulfuric acid, salt formation, hydroxylation, chlorination, dehydroxylation, reduction, esterification |
| 09/27/2005 | US6949648 Condensed pyrazole derivatives, process for producing the same and use thereof |
| 09/27/2005 | US6949646 Nitrogen compounds such as 2-Butyl-1-(2-methylpropyl)-1H-tetrazolo[1,5-a]imidazo[4,5-c][1,8]naphthyridine, used to induce biosynthesis of cytokines such as interferons and tumor necrosis factors, or for prophylaxis of viral diseases |
| 09/27/2005 | US6949643 Thiazolopytimidines and their use as modulators of chemokine receptor activity |
| 09/27/2005 | US6949585 Cytokine antagonist; immunology, viricides, antitumor agents, anticancer agents |
| 09/27/2005 | US6949580 Anticancer agents; restenosis; antiinflammatory agents; cardiovascular disorders |
| 09/27/2005 | US6949575 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives |
| 09/27/2005 | US6949574 (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 09/27/2005 | US6949572 Antilipemic or antilipolytic agents for treatment of obesity and lipid disorders, S)-N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide |
| 09/27/2005 | US6949571 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. |
| 09/27/2005 | US6949568 Such as N-(2-(4-(3-phenyl-4-methoxyphenyl)aminophenyl)ethyl)-2-hydroxy-2-(3 -hydroxymethyl-4-hydroxyphenyl)ethylamine; for treatment of chronic obstructive pulmonary disease |
| 09/27/2005 | US6949566 For use as metalloproteinase inhibitors |
| 09/27/2005 | US6949565 Protein kinase inhibitors |
| 09/27/2005 | US6949564 NPY-5 antagonists |
| 09/27/2005 | US6949562 Heterocyclic compounds as ligands of the GABAA receptor |
| 09/27/2005 | US6949561 polycyclic compound comprises sulphamate group attached to one of the ring components, wherein ring is naphtho(2,1-f)quinoline |
| 09/27/2005 | US6949548 administering a synergistic combination of levosimendan or a pharmaceutically acceptable salt thereof and a beta-adrenergic receptor antagonist to a patient in need of such treatment |
| 09/27/2005 | US6949547 Antidiabetic agents; central nervous system disorders; cardiovascular disorders; hypotensive agents; anticancer agents |
| 09/27/2005 | US6949546 N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity |
| 09/27/2005 | US6949545 Tissue remodeling; antiinflammatory agents; autoimmune disease |
| 09/27/2005 | US6949544 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 09/27/2005 | US6949541 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof |
| 09/27/2005 | US6949538 Compounds, compositions, and methods |
| 09/27/2005 | US6949535 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one |
| 09/27/2005 | US6949525 In particular the treatment of osteochondral lesions associated with osteoarthritis by means of intraarticular application of a mixture of hyaluronate and chondroitin sulfate |
| 09/27/2005 | US6949521 Therapeutic azide compounds |
| 09/27/2005 | US6949515 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases |
| 09/27/2005 | US6949512 administering to patient effective amount of lipopolysaccharide binding protein to elevate serum concentration of lipopolysaccharide binding protein in patient to sufficiently high level to suppress lipopolysaccharide induced release of cytokine |
| 09/27/2005 | US6949510 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/27/2005 | US6949506 Relaxin-like factor and methods and uses thereof |
| 09/27/2005 | US6949380 culturing a proliferating epidermal basal cell population, exposing the cell(s) to fetuin, noggin, chordin, gremlin, follistatin, growing the cell(s) in the presence of an antisense oligonucleotide antagonist of bone morphogenetic protein (BMP) |
| 09/27/2005 | US6949263 Method for preparing nicotianamine or nicotianamine-containing product |
| 09/27/2005 | US6949257 Substance P antagonist; antidepressants; central nervous system disorders; respiratory system disorders |
| 09/27/2005 | US6949087 Apparatus with weeping tip and method of use |
| 09/22/2005 | WO2005087775A1 Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient |
| 09/22/2005 | WO2005087762A1 Novel indole derivative for alkylating specific base sequence of dna and alkylating agent and drug each comprising the same |
| 09/22/2005 | WO2005087749A1 2-aminoquinazoline derivative |
| 09/22/2005 | WO2005087713A1 Amide compound, pharmaceutical composition and rxr function control agent |
| 09/22/2005 | WO2005087710A1 Aminophenylpropanoic acid derivative |
| 09/22/2005 | WO2005087245A1 TESTOSTERONE 5α-REDUCTASE INHIBITOR |
| 09/22/2005 | WO2005087022A1 Food composition having antistress effect |
| 09/22/2005 | WO2003099270A8 Methods of treating allergic reactions |
| 09/22/2005 | WO2003065997A3 Anti-infarction molecules |
| 09/22/2005 | US20050210538 Screening for a developmental promoter or a developmental suppressor of oligodendrocytes, or a promoter or a suppressor of myelinogenesis, diagnostic for neuropsychiatric disorders |
| 09/22/2005 | US20050209459 Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles |
| 09/22/2005 | US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents |
| 09/22/2005 | US20050209452 Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 09/22/2005 | US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders |
| 09/22/2005 | US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/22/2005 | US20050209329 Potentiation of therapeutic effects of fatty acids |
| 09/22/2005 | US20050209310 Methods for modulating tumor growth and metastasis |
| 09/22/2005 | US20050209309 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same |
| 09/22/2005 | US20050209306 Crystalline [R-(R*,R*)]-2-(4-fluorophenyI)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl- 4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1) |
| 09/22/2005 | US20050209292 Cancer therapy |
| 09/22/2005 | US20050209281 Salt formation by dissolving donepezil in ethanol, adding hydrogen chloride, forming polymorphic crystal; simplification; safety to environment and the bodies of operators; and can produce at low costs |
| 09/22/2005 | US20050209273 Neuroprotectants, analgesics or anticonvulsants |
| 09/22/2005 | US20050209272 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 09/22/2005 | US20050209270 Use of 5HT3 agonists for relaxing the fundus |
| 09/22/2005 | US20050209267 Thioether substituted imidazoquinolines |
| 09/22/2005 | US20050209261 Rho-kinase inhibitors |
| 09/22/2005 | US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/22/2005 | US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/22/2005 | US20050209235 Tyrosine kinase inhibitors; antiproliferative agent; 2-(4-{4-[1-(3-Fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl}-[1,4]diazepan-1-yl)-ethanol combined with anticarncer agent selected from tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate and other |
| 09/22/2005 | US20050209234 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds |
| 09/22/2005 | US20050209230 2,4-Pyrimidinediamine compounds and their uses |
| 09/22/2005 | US20050209229 Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib |
| 09/22/2005 | US20050209228 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site |
| 09/22/2005 | US20050209225 Substituted indoles and their use as integrin antagonists |
| 09/22/2005 | US20050209217 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors |
| 09/22/2005 | US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline |
| 09/22/2005 | US20050209214 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209213 Quinoline compound |
| 09/22/2005 | US20050209198 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/22/2005 | US20050209197 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds |
| 09/22/2005 | US20050209192 Autoimmune disorders; modulating protein kinase C activity |
| 09/22/2005 | US20050209191 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209161 Drugs for treatment of inflammation/blood brain barrier degradation;administering to a subject in need of such treatment, a pharmaceutically effective amount of a peptide antagonist of zonulin, wherein the peptide antagonist binds to a zonula occludens toxin receptor |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist |
| 09/22/2005 | US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 09/22/2005 | US20050208552 Corpuscles of Stannius protein, stanniocalcin |
| 09/22/2005 | US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response |
| 09/22/2005 | US20050208198 Ultrafiltration/microfiltration to separate fibers from starch residues; electrodialysis |
| 09/22/2005 | US20050208197 Agonists/antagonists of muscarine M3 receptors, obtained from beer through isolation and purification; distillation; chromatography; side effect reduction |
| 09/22/2005 | US20050208128 Immediate release tablet |
| 09/22/2005 | US20050208124 Drugs containing riboflavin-type compounds |
| 09/22/2005 | US20050208103 Contacting sclera with a therapeutic or diagnostic agent so as to permit its passage into the choroidal and retinal tissues; no significant systemic absorption or tissue damage; eye disorders |
| 09/22/2005 | US20050208079 Glucan-based vaccines |
| 09/22/2005 | US20050208064 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide |
| 09/22/2005 | US20050208035 Nutritional composition for treating an immune condition |
| 09/22/2005 | US20050208015 Glycerol derivative |
| 09/22/2005 | US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid |
| 09/22/2005 | US20050207976 High energy phototherapeutic agents |